-+ 0.00%
-+ 0.00%
-+ 0.00%

Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial

PUBT·08/27/2026 11:31:56
Listen to the news
Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial
  • Corvus reported peer-reviewed final Phase 1/1b data for soquelitinib in T-cell lymphoma published in Blood; results were previously generated, not future-presented.
  • Study showed durable anti-tumor activity in heavily pre-treated patients, including complete responses, with a tolerable safety profile.
  • Findings support ongoing registration Phase 3 testing in relapsed or refractory peripheral T-cell lymphoma versus physician’s choice chemotherapy options.
  • Mechanism data linked activity to immune rebalancing effects in blood and tumor samples, supporting expansion into inflammatory diseases.
  • Company is enrolling a Phase 2 trial in atopic dermatitis, with additional trials planned in hidradenitis suppurativa and asthma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270730PRIMZONEFULLFEED9816961) on August 27, 2026, and is solely responsible for the information contained therein.